Intellia Therapeutics Company Insiders
NTLA Stock | USD 14.30 0.50 3.62% |
Intellia Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Intellia Therapeutics suggests that vertually all insiders are panicking. Intellia Therapeutics employs about 526 people. The company is managed by 12 executives with a total tenure of roughly 5 years, averaging almost 0.0 years of service per executive, having 43.83 employees per reported executive.
Nessan Bermingham CEO President CEO, Founder, Director |
Laura SeppLorenzino President Executive Vice President Chief Scientific Officer |
Intellia Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-10-02 | Michael P Dube | Disposed 2012 @ 19.01 | View | ||
2024-07-01 | Eliana Clark | Disposed 405 @ 22.93 | View | ||
2024-03-04 | James Basta | Disposed 2297 @ 32.99 | View | ||
2024-01-08 | Laura Sepp-Lorenzino | Disposed 2275 @ 28.87 | View | ||
2024-01-03 | John M Leonard | Disposed 19223 @ 29.46 | View |
Monitoring Intellia Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Intellia |
Intellia Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Intellia Therapeutics' future performance. Based on our forecasts, it is anticipated that Intellia will maintain a workforce of about 530 employees by December 2024.Intellia Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2781) % which means that it has lost $0.2781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5223) %, meaning that it created substantial loss on money invested by shareholders. Intellia Therapeutics' management efficiency ratios could be used to measure how well Intellia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.39. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Intellia Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 317.8 M, whereas Total Assets are forecasted to decline to about 686.6 M.As of November 25, 2024, Common Stock Shares Outstanding is expected to decline to about 50.5 M. The current year's Net Loss is expected to grow to about (405.4 M)
Intellia Therapeutics Workforce Comparison
Intellia Therapeutics is regarded third in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 9,444. Intellia Therapeutics holds roughly 526 in number of employees claiming about 6% of equities under Health Care industry.
Intellia Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intellia Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intellia Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Intellia Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 3.0 | 3 | 1 | 180,344 | 405.00 |
2024-06-01 | 7.0 | 14 | 2 | 153,218 | 1,505 |
2024-03-01 | 1.125 | 18 | 16 | 779,634 | 71,027 |
2023-06-01 | 5.6667 | 17 | 3 | 99,922 | 10,000 |
2023-03-01 | 1.3333 | 20 | 15 | 643,512 | 40,070 |
2022-03-01 | 2.875 | 23 | 8 | 372,732 | 23,302 |
2021-12-01 | 0.2105 | 4 | 19 | 17,300 | 34,600 |
2021-09-01 | 0.2838 | 21 | 74 | 496,280 | 724,637 |
2021-06-01 | 0.3971 | 27 | 68 | 256,624 | 1,401,019 |
2021-03-01 | 0.5435 | 25 | 46 | 1,234,160 | 1,372,373 |
2020-12-01 | 0.7045 | 31 | 44 | 439,675 | 586,549 |
2020-09-01 | 0.5 | 6 | 12 | 45,000 | 76,845 |
2020-06-01 | 1.6667 | 10 | 6 | 339,000 | 41,230 |
2018-06-01 | 0.8333 | 5 | 6 | 99,500 | 64,272 |
2018-03-01 | 1.0 | 5 | 5 | 278,410 | 597,890 |
2017-12-01 | 0.4545 | 5 | 11 | 515,000 | 2,196,566 |
2017-09-01 | 0.25 | 2 | 8 | 76,000 | 2,397,692 |
2017-03-01 | 1.6 | 8 | 5 | 878,245 | 742,264 |
2016-06-01 | 0.8222 | 37 | 45 | 33,026,396 | 60,056,189 |
Intellia Therapeutics Notable Stakeholders
An Intellia Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intellia Therapeutics often face trade-offs trying to please all of them. Intellia Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intellia Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Rodolphe MBA | Founder Board | Profile | |
Nessan Bermingham | President CEO, Founder, Director | Profile | |
John MD | CEO President | Profile | |
Laura SeppLorenzino | Executive Vice President Chief Scientific Officer | Profile | |
JD Esq | General VP | Profile | |
Jennifer Doudna | Founder Board | Profile | |
Rachel Haurwitz | CoFounder | Profile | |
Glenn CPA | CFO VP | Profile | |
Derek Hicks | Executive Officer | Profile | |
Andrew May | Founder Board | Profile | |
David MD | Executive Officer | Profile | |
Derrick Rossi | Founder Board | Profile |
About Intellia Therapeutics Management Performance
The success or failure of an entity such as Intellia Therapeutics often depends on how effective the management is. Intellia Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intellia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intellia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.37) | (0.39) | |
Return On Capital Employed | (0.43) | (0.46) | |
Return On Assets | (0.37) | (0.39) | |
Return On Equity | (0.46) | (0.48) |
Please note, the presentation of Intellia Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intellia Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Intellia Therapeutics' management manipulating its earnings.
Intellia Therapeutics Workforce Analysis
Traditionally, organizations such as Intellia Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intellia Therapeutics within its industry.Intellia Therapeutics Manpower Efficiency
Return on Intellia Therapeutics Manpower
Revenue Per Employee | 69K | |
Revenue Per Executive | 3M | |
Net Loss Per Employee | 914.8K | |
Net Loss Per Executive | 40.1M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 73.6M |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |